phrykt

INVO Fertility, Inc. (IVF): who owns it and who trades it

As of Nov 16, 2026, IVF insiders reported 1 open-market sale worth $6 and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Matthew K Szot (Director), with $6.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, IVF insiders reported $0 of open-market purchases and $6 of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$6
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Dec 3, 2025
Filed Dec 5, 2025

Purchases and sales by month

$6$6DecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Dec 3, 2025Matthew K SzotDirectorSale4$1.52$6Form 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Matthew K SzotDirector–$6Dec 3, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

IVF short interest

Low short interest. 0.4% of IVF shares are sold short: about 1 share in 236. Over the last 12 reports the number of shares short went down 94%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 7,572 IVF shares were sold short, 0.4% of the shares outstanding, down 71.4% from the report before. At the average daily volume of 31,162 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.42%May 15Oct 3048.9%

Days to cover

1.0May 15Oct 304.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20267,5720.42%-71%31,1621.0
Oct 15, 202626,4781.48%-47%140,4701.0
Sep 30, 202650,1182.81%-74%151,1041.0
Sep 15, 2026193,69510.84%-47%138,9171.4
Aug 31, 2026367,54820.58%+61%11.71M1.0
Aug 14, 2026228,46012.79%-5%55,9484.1
Jul 31, 2026240,80013.48%-7%104,1142.3
Jul 15, 2026260,11414.56%-66%358,6781.0
Jun 30, 2026760,24242.57%+462%12.66M1.0
Jun 15, 2026135,347–+47%268,1311.0
May 29, 202692,1960.61%-25%1.44M1.0
May 15, 2026123,0760.81%+17%46,6922.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

INVO Fertility company events

INVO Fertility filed 19 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, restatement, listing). The latest was on Nov 4, 2026.

  1. Nov 4, 2026AnnouncementOn October 27, 2026 the Company issued a press release announcing the Reverse Stock Split. Filing
  2. Aug 28, 2026AnnouncementAs previously reported, on July 24, 2026, the Company entered into an Any Market Purchase Agreement with Alumni Capital LP, pursuant to which the Company has the right, but not the obligation, to sell to the Investor up to an aggregate of $15 million, unless the Company and the Investor mutually… Filing
  3. Aug 17, 2026ResultsReleased financial results. Filing
  4. Jul 24, 2026AgreementINVO Fertility Inc. entered into an Any Market Purchase Agreement with Alumni Capital LP. Filing
  5. Jun 25, 2026AgreementINVO Centers, LLC, a Delaware limited liability company, a wholly owned subsidiary of INVO Fertility Inc., a Nevada corporation, is a party to that certain limited liability company agreement of HRCFG INVO LLC with HRCFG, LLC to establish a joint venture partnership for a fertility clinic in… Filing
  6. Jun 22, 2026ResultsReleased financial results. Filing
  7. Jun 16, 2026AnnouncementShared information with investors. Filing
  8. Jun 2, 2026ResultsReleased financial results. Filing
  9. Jun 2, 2026RestatementThe previously issued unaudited consolidated financial statements of INVO Fertility, Inc. as of March 31, 2025, June 30, 2025, and September 30, 2025 and the respective periods then ended are being restated as a result of an internal review. Filing
  10. Apr 29, 2026ListingINVO Fertility, Inc. received a letter from the Listing Qualifications staff of The Nasdaq Stock Market LLC indicating that the Company failed to file its Annual Report on Form 10-K for the year ended December 31, 2025, on a timely basis and, as such, no longer satisfies Nasdaq Listing Rule… Filing
  11. Mar 31, 2026AnnouncementOn March 25, 2026 the Company issued a press release announcing the Reverse Stock Split. Filing
  12. Feb 24, 2026DealBelow, on February 18, 2026, INVO Fertility Inc., a Nevada corporation, consummated the acquisition of the Clinic (as defined under Item 2.01 below) by, Wood Violet Fertility LLC, a Delaware limited liability company and wholly owned subsidiary of INVO Centers LLC, a Delaware company wholly owned… Filing
  13. Jan 30, 2026AgreementINVO Fertility, Inc. entered into an inducement letter agreement with an institutional investor and existing holder of certain existing warrants to purchase up to 4,733,728 shares of the Company’s common stock. Filing
  14. Jan 26, 2026VoteReported shareholder vote results. Filing
  15. Jan 6, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
  16. Dec 17, 2025AgreementINVO Fertility, Inc., a Nevada corporation, through its wholly owned subsidiary, INVO Centers LLC, a Delaware limited liability company, entered into an asset purchase agreement by and among the Buyer, Family Beginnings, P.C., an Indiana professional service corporation, and James Donahue MD to… Filing
  17. Dec 5, 2025AgreementINVO Fertility, Inc., a Nevada corporation, entered into a securities purchase agreement with an institutional investor, pursuant to which the Company agreed to issue and sell securities of the Company, in the aggregate amount of approximately $4 million, comprised of 235,000 shares of common stock… Filing
  18. Dec 3, 2025AnnouncementThe Company issued a press release announcing the Reverse Stock Split. Filing
  19. Nov 17, 2025ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

INVO Fertility financials

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named IVF in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Alumni Capital LP13G/A10.0%
Nov 16, 2026Alumni Capital LP13G/A10.0%
Oct 9, 2026Glenbrook Capital Management13G/A1.4%
Oct 9, 2026Glenbrook Capital Management13G/A1.4%

Questions about INVO Fertility, Inc. (IVF) stock

Are IVF insiders buying or selling?

In the last 12 months, IVF insiders reported no open-market purchases and 1 sale worth $6. The latest trade was on Dec 3, 2025. See every trade.

What is the short interest in IVF?

As of Oct 30, 2026, 7,572 IVF shares were sold short, 0.4% of the shares outstanding, down 71.4% from the report before. At the average daily volume of 31,162 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Executive pay

INVO Fertility's chief executive was paid a total of $431K for the year ended Dec 31, 2025, up 66% from $260K the year before. In the last 12 months, INVO Fertility's executives and directors bought no stock on the open market and sold $6.

Chief executive, total pay$431KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$390KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$181KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.